Skip to main navigation
  • Skip to main content
Checkmate Pharmaceuticals
  • Publications & Resources
  • Investors
    • Overview
    • News & Events
      • Press Releases
      • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Analyst Coverage
    • Governance
      • Documents & Charters
      • Leadership
      • Board of Directors
      • Committee Composition
    • Financials
      • SEC Filings
    • Investor Resources
      • Investor FAQs
      • Contact IR
      • Email Alerts
  • Careers
  • Contact
  • Our Story
  • Our Science
    • Vidutolimod Platform/Technology
    • Mechanism of Action
    • Pipeline
    • Glossary of Terms
  • Our Difference
  • Our People
    • Leadership
    • Board of Directors
  • Clinical Trials
    • Melanoma
    • HNSCC
    • Expanded Access Policy
  • Publications & Resources
  • Investors
    • Overview
    • News & Events
      • Press Releases
      • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • Governance
      • Documents & Charters
      • Leadership
      • Board of Directors
      • Committee Composition
    • Financials
      • SEC Filings
    • Investor Resources
      • Investor FAQs
      • Contact IR
      • Email Alerts
  • Careers
  • Contact

Press Releases

Press Releases
Events & Presentations
Checkmate Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update
May 12, 2022
Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types
Apr 19, 2022
Checkmate Pharmaceuticals Presents Clinical Trial Biomarker Data with Vidutolimod at the 2022 American Association for Cancer Research (AACR) Annual Meeting
Apr 08, 2022
Checkmate Pharmaceuticals Announces Full Year 2021 Financial Results and Provides Business Update
Mar 29, 2022
Checkmate Pharmaceuticals to Present at the 2022 American Association for Cancer Research (AACR) Annual Meeting
Mar 08, 2022
Checkmate Pharmaceuticals Appoints Alan Bash as President and CEO
Feb 09, 2022
Checkmate Pharmaceuticals Welcomes Industry Leader Jon Wigginton, M.D. to its Board of Directors
Jan 31, 2022
Checkmate Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference
Jan 03, 2022

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Checkmate disavows any obligation to update the information contained in such press releases after the date of their issuance.

Contact Us
Privacy Policy

Checkmate Pharmaceuticals   I   245 Main Street, 2nd Floor   I   Cambridge, MA 02142
617.682.3625
admin@checkmatepharma.com

© Checkmate Pharmaceuticals. All rights reserved. Created in the USA. CMP-WEB-001-01 07/2021